BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TAK-442: Development discontinued

Takeda discontinued development of TAK-442 based in part on its full analysis of the 3-stage, double-blind, international Phase II AXIOM-ACS trial in 2,753 patients with ACS. The trial showed that there were no significant differences between all doses of TAK-442 and placebo in the incidence of major bleeding, the primary endpoint. Specifically, once-daily 40, 80 and 160 mg...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >